Quote:

---

If your investment thesis is to follow the flow of government money then . . . are buys at this point, however if you believe that the will of the American people will be heard in the next 6-8 weeks with an approval of leronlimab then CYDY is clearly the better investment vehicle with only a $1.5 billion market cap. The first drug that takes dying from COVID-19 off the table should be worth north of $10 billion ($17.00/share).

---